Clinical Trial Update: Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD) [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing two aflibercept regimens in neovascular age-related macular degeneration completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Bayer | Conditions: Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2021-04-08